Blockade of renin-angiotensin system attenuates advanced glycation end products-mediated signaling pathways

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 6, 2010, Pages 590-600

  Kamioka, Masashi ^a   Ishibashi, Toshiyuki ^a   Sugimoto, Koichi ^a   Uekita, Hironori ^a   Nagai, Ryoji ^b   Sakamoto, Nobuo ^a   Ando, Katsuya ^a   Ohkawara, Hiroshi ^a   Teramoto, Tamio ^c   Maruyama, Yukio ^d   Takeishi, Yasuchika ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b JAPAN WOMEN'S UNIVERSITY   (Japan)

^c TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d HOSHI GENERAL HOSPITAL   (Japan)

Author keywords

ACE inhibitor; Apoptosis; ARB; MMP 9; Rac1

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; OLMESARTAN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P47; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TEMOCAPRILAT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE; THIAZEPINE DERIVATIVE;

ANIMAL CELL; AORTA MEDIA; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MACROPHAGE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RABBIT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; AORTA; CELL CULTURE; CYTOLOGY; DIABETIC ANGIOPATHIES; DRUG EFFECTS; METABOLISM; SMOOTH MUSCLE FIBER;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA; CELLS, CULTURED; DIABETIC ANGIOPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; IMIDAZOLES; MYOCYTES, SMOOTH MUSCLE; NADPH OXIDASE; RABBITS; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; TETRAZOLES; THIAZEPINES;

EID: 77954691788     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.3624     Document Type: Article

References (50)

1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Brit Med J, 2000; 321: 405-412
2. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA, 2002; 287: 2570-2581
3. Qiao Q, Tuomilehto J, Borch-Johnsen K: Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia, 2003; 46: M17-M21
4. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation, 2006; 114: 597-605
5. Orasanu G, Plutzky J: The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol, 2009; 53 (5 Suppl): S35-S42
6. Basta G, Schmidt AM, De Caterina R: Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res, 2004; 63: 582-592
7. Monnier VM, Cerami A: Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science, 1981; 211: 491-493
8. Makita Z, Vlassara H, Cerami A, Bucala R: Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem, 1992; 267: 5133-5138
9. Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, Dohi K, Makita Z, Vlassara H, Bucala R: Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol, 1993; 143: 1649-1656
10. Haffner SM, Lehto S, Ronnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 1998; 339: 229-234
11. Sobel BE: Optimizing cardiovascular outcomes in diabetes mellitus. Am J Med, 2007; 120 (9 Suppl 2): S3-11
12. Gao L, Mann GE: Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc Res, 2009; 82: 9-20
13. Yamagishi S, Nakamura K, Matsui T, Inagaki Y, Takenaka K, Jinnouchi Y, Yoshida Y, Matsuura T, Narama I, Motomiya Y, Takeuchi M, Inoue H, Yoshimura A, Bucala R, Imaizumi T: Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen speciesmediated vascular endothelial growth factor expression. J Biol Chem, 2006; 281: 20213-20220
14. Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation, 2001; 104: 365-372
15. Heistad DD: Unstable coronary-artery plaques. N Engl J Med, 2003; 349: 2285-2287
16. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 2003; 348: 383-393
17. Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med, 2008; 358: 580-591
18. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004; 364: 685-696
19. Klein L, Gheorghiade M: Management of the patient with diabetes mellitus and myocardial infarction: clinical trials update. Am J Med, 2004; 116 Suppl 5A: 47S-63S
20. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet, 2000; 355: 253-259
21. Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML: EUROPA Investigators. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J, 2005; 26: 1369-1378
22. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C: Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med, 2008; 358: 1547-1559
23. Ohkawara H, Ishibashi T, Sakamoto T, Sugimoto K, Nagata K, Yokoyama K, Sakamoto N, Kamioka M, Matsuoka I, Fukuhara S, Sugimoto N, Takuwa Y, Maruyama Y: Thrombin-induced rapid geranylgeranylation of RhoA as an essential process for RhoA activation in endothelial cells. J Biol Chem, 2005; 280: 10182-10188
24. 2+ signaling pathways in endothelial cells. J Cell Physiol, 2009; 220: 706-715
25. Nagai R, Matsumoto K, Ling X, Suzuki H, Araki T, Horiuchi S: Glycolaldehyde, a reactive intermediate for advanced glycation end products, plays an important role in the generation of an active ligand for the macrophage scavenger receptor. Diabetes, 2000; 49: 1714-1723
26. ε-(carboxymethyl) lysine by the cleavage of Amadori product and generation of glucosone and glyoxal from glucose: novel pathways for protein modification by peroxynitrite. Diabetes, 2002; 51: 2833-2839
27. Nagata K, Ishibashi T, Sakamoto T, Nakazato K, Seino Y, Yokoyama K, Ohkawara H, Teramoto T, Maruyama Y: Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human cultured monocytes. J Hypertens, 2001; 19: 775-783
28. Nakazato K, Ishibashi T, Nagata K, Seino Y, Wada Y, Sakamoto T, Matsuoka R, Teramoto T, Sekimata M, Homma Y, Maruyama Y: Expression of very low density lipoprotein receptor mRNA in circulating human monocytes: its up-regulation by hypoxia. Atherosclerosis, 2001; 155: 439-444
29. Ishibashi T, Sakamoto T, Ohkawara H, Nagata K, Sugimoto K, Sakurada S, Sugimoto N, Watanabe A, Yokoyama K, Sakamoto N, Kurabayashi M, Takuwa Y, Maruyama Y: Integral role of RhoA activation in monocyte adhesiontriggered tissue factor expression in endothelial cells. Arte-rioscler Thromb Vasc Biol, 2003; 23: 681-687
30. 2+ influx through MCP-1 in endothelial cells by monocyte adhesion. Arterioscler Thromb Vasc Biol, 2005; 25: 2005-2011
31. 2+ signaling. Atherosclerosis, 2007; 193: 44-54
32. 2+ influx in tissue factor expression in monocyte adhesion to endothelial cells. J Atheroscler Thromb, 2007; 14: 109-115
33. Shindo J, Ishibashi T, Yokoyama K, Nakazato K, Ohwada T, Shiomi M, Maruyama Y: Granulocyte-macrophage colony-stimulating factor prevents the progression of atherosclerosis via changes in the cellular and extracellular composition of atherosclerotic lesions in watanabe heritable hyperlipidemic rabbits. Circulation, 1999; 99: 2150-2156
34. Dong Z, Bonfil RD, Chinni S, Deng X, Trindade Filho JC, Bernardo M, Vaishampayan U, Che M, Sloane BF, Sheng S, Fridman R, Cher ML: Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol, 2005; 166: 1173-1186
35. Hodroj W, Legedz L, Foudi N, Cerutti C, Bourdillon MC, Feugier P, Beylot M, Randon J, Bricca G: Increased insulin-stimulated expression of arterial angiotensinogen and angiotensin type 1 receptor in patients with type 2 diabetes mellitus and atheroma. Arterioscler Thromb Vasc Biol, 2007; 27: 525-531
36. Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, Fukami K, Okuda S, Imaizumi T: Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc Res, 2008; 75: 130-134
37. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K: Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol, 2002; 13: 2478-2487
38. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LA, Jerums G, Osicka TM: Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes, 2002; 51: 3274-3282
39. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stern DM, Schmidt AM: RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation, 2002; 106: 2827-2835
40. Zhou Z, Wang K, Penn MS, Marso SP, Lauer MA, Forudi F, Zhou X, Qu W, Lu Y, Stern DM, Schmidt AM, Lincoff AM, Topol EJ: Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation. 2003; 107: 2238-2243
41. Gao X, Zhang H, Schmidt AM, Zhang C: AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am J Physiol Heart Circ Physiol, 2008; 295: H491-H498
42. Fujita M, Okuda H, Tsukamoto O, Asano Y, Hirata YL, Kim J, Miyatsuka T, Takashima S, Minamino T, Tomoike H, Kitakaze M: Blockade of angiotensin II receptors reduces the expression of receptors for advanced glycation end products in human endothelial cells. Arterioscler Thromb Vasc Biol, 2006; 26: e138-e142
43. Aikawa M, Rabkin E, Sugiyama S, Voglic SJ, Fukumoto Y, Furukawa Y, Shiomi M, Schoen FJ, Libby P: An HMGCoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation, 2001; 103: 276-283
44. van Hinsbergh VW, Engelse MA, Quax PH: Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol, 2006; 26: 716-728
45. Ishibashi T, Kawaguchi M, Sugimoto K, Uekita H, Sakamoto N, Yokoyama K, Maruyama Y, Takeishi Y. Advanced Glycation End Products-Mediated Matrix Metalloproteinase-9 and Apoptosis via Renin-Angiotensin System in Type 2 Diabetes. J Atheroscler Thromb, (in press)
46. Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ, Farb A, Virmani R: Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol, 2004; 24: 1266-1271
47. Shoji T, Koyama H, Morioka T, Tanaka S, Kizu A, Motoyama K, Mori K, Fukumoto S, Shioi A, Shimogaito N, Takeuchi M, Yamamoto Y, Yonekura H, Yamamoto H, Nishizawa Y: Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes, 2006; 55: 2245-2255
48. Kelly DJ, Cox AJ, Tolcos M, Cooper ME, Wilkinson-Berka JL, Gilbert RE: Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney Int, 2002; 61: 31-39
49. Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A, Kajstura J: Myocyte death in streptozotocininduced diabetes in rats in angiotensin II- dependent. Lab Invest, 2000; 80: 513-527
50. Alikhani Z, Alikhani M, Boyd CM, Nagao K, Trackman PC, Graves DT: advanced glycation end products enhance expression of pro-apoptotic genes and stimulate fibroblast apoptosis through cytoplasmic and mitochondrial pathways. J Biol Chem, 2005; 280: 12087-12095